CureVac's COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge InfectionAccesswire • 01/11/21
This Covid Vaccine Stock Just Rocketed On A Deal With Pharma Giant BayerInvestors Business Daily • 01/07/21
CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare WorkersAccesswire • 12/21/20
German vaccine maker CureVac ramps up capacity to 300 million COVID-19 doses in 2021Market Watch • 11/17/20
3 mRNA Coronavirus Vaccine Stocks to Check Out That Aren't Pfizer, BioNTech, or ModernaThe Motley Fool • 11/17/20